Comparison of HPV sign Genotyping Test with INNO-LiPA HPV Genotyping Extra assay on histologic and cytologic cervical specimens

Diagnostic Microbiology and Infectious Disease

Volumn 74, Issue 1, 2012, Pages 43-48

  Barbieri, Daniela ^a   Nocera, Martina ^b   Gallinella, Giorgio ^a,b   Gentilomi, Giovanna Angela ^a,b   Plazzi, Marinella ^a,b   Costa, Sivano ^b   Santini, Donatella ^b   Venturoli, Simona ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cervical cancer; Diagnostic virology; Genotyping; HPV; Pyrosequencing

Indexed keywords

ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; INTERMETHOD COMPARISON; MIXED INFECTION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; QUANTITATIVE REAL TIME POLYMERASE CHAIN REACTION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS LOAD; VIRUS TYPING; WART VIRUS;

CERVIX UTERI; FEMALE; GENOTYPE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; VIROLOGY;

EID: 84865294513     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.05.014     Document Type: Article

References (28)

1. Altman D.G., Machin D., Bryant T.N., Gardner M.J. Statistics with confidence 2000, JW Arrowsmith, Bristol. 2nd ed.
2. Barzon L., Militello V., Lavezzo E., Franchin E., Peta E., Squarzon L., et al. Human papillomavirus genotyping by 454 next generation sequencing technology. J Clin Virol 2011, 52:93-97.
3. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244-265.
4. Bulkmans N.W., Bleeker M.C., Berkhof J., Voorhorst F.J., Snijders P.J., Meijer C.J. Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. Int J Cancer 2005, 117:177-181.
5. Cogliano V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005, 6:204.
6. Cricca M., Morselli-Labate A.M., Venturoli S., Ambretti S., Gentilomi G.A., Gallinella G., et al. Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. Gynecol Oncol 2007, 106:549-557.
7. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006, 119:1095-1101.
8. Didelot-Rousseau M.N., Courgnaud V., Nagot N., Ouedraogo A., Konate I., Mayaud P., et al. Comparison of INNO-LiPA HPV Genotyping v2 with PCR product subcloning and sequencing for identification of genital human papillomavirus genotypes in African women. J Virol Methods 2006, 135:181-185.
9. Fleiss J.L. Statistical methods for rates and proportion 1981, John Wiley & Sons Inc, New York. 2nd ed.
10. Gharizadeh B., Kalantari M., Garcia C.A., Johansson B., Nyrén P. Typing of human papillomavirus by pyrosequencing. Lab Invest 2001, 81:673-679.
11. Gharizadeh B., Ghaderi M., Donnelly D., Amini B., Wallin K.L., Nyrén P. Multiple-primer DNA sequencing method. Electrophoresis 2003, 24:1145-1151.
12. Gharizadeh B., Oggionni M., Zheng B., Akom E., Pourmand N., Ahmadian A., et al. Type-specific multiple sequencing primers. J Mol Diagn 2005, 7:198-205.
13. Giorgi Rossi P., Bisanzi S., Paganini I., Di Iasi A., Angeloni C., Scalisi A., Macis R., Pini M.T., Chini F., Carozzi F.M. Prevalence of HPV high and low risk types in cervical samples from the Italian general population: a population based study. BMC Infect Dis 2010, 10:214.
14. Ho G.Y., Burk R.D., Klein S., Kadish A.S., Chang C.J., Palan P., et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995, 87:1365-1371.
15. Kjær S.K., Frederiksen K., Munk C., Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010, 102:1478-1488.
16. Lichtig H., Algrisi M., Botzer L.E., Abadi T., Verbitzky Y., Jackman A. HPV16 E6 natural variants exhibit different activities in functional assays relevant to the carcinogenic potential of E6. Virology 2006, 350:216-227.
17. Nobbenhuis M.A., Walboomers J.M., Helmerhorst T.J., Rozendaal L., Remmink A.J., Risse E.K., et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999, 354:20-25.
18. Perrons C., Kleter B., Jelley R., Jalal H., Quint W., Tedder R. Detection and genotyping of human papillomavirus DNA by SPF10 and MY09/11 primers in cervical cells taken from women attending a colposcopy clinic. J Med Virol 2002, 67:246-252.
19. Poljak M., Kocjan B.J. Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev Anti Infect Ther 2010, 8:1139-1162.
20. Qu W., Jiang G., Cruz Y., Chang C.J., Ho G.Y.F., Klein R.S., et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5/GP6 primer systems. J Clin Microbiol 1997, 35:1304-1310.
21. Ronco G., Giorgi Rossi P. New paradigms in cervical cancer prevention: opportunities and risks. BMC Womens Health 2008, 8:23.
22. Saslow D., Runowicz C.D., Solomon D., Moscicki A.B., Smith R.A., Eyre H.J., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002, 52:342-362.
23. Sichero L., Ferreira S., Trottier H., Duarte-Franco E., Ferenczy A., Franco E.L., et al. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer 2007, 120:1763-1768.
24. van Doorn L.J., Quint W., Kleter B., Molijn A., Colau B., Martin M.T., et al. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol 2002, 40:979-983.
25. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
26. Wright T.C., Cox J.T., Massad L.S., Twiggs L.B., Wilkinson E.J. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. J Low Genit Tract Dis 2002, 6:127-143.
27. Wright T.C., Schiffman M., Solomon D., Cox J.T., Garcia F., Goldie S., et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004, 103:304-309.
28. Zubach V., Smart G., Ratnam S., Severini A. A novel microsphere-based method for the detection and typing of 46 mucosal human papillomavirus types. J Clin Microbiol 2012, 50:460-464.